Compare GSK plc (GSK) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Phillips 66 — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while Phillips 66 trades at $201.98 (market cap $78.65B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | PSX | |
|---|---|---|
Market Cap | $101.34B | $78.65B |
Sector | Health | Energy |
52-Week High | $61.18 | $201.45 |
52-Week Low | $36.20 | $118.37 |
Enterprise Value | $121.95B | $100.62B |
Dividend Yield | 3.49% | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Phillips 66 (PSX) trades at $201.45, up 1.59% on the day, with a bullish technical signal and strong analyst support. The stock has beaten earnings estimates for the last three quarters, though revenue has declined from $170.0B in 2022 to $132.4B in 2025 (SEC filings, 2025). Valuation ratios appear reasonable with a P/E of 19.38 and P/S of 0.59, while recent news highlights refining strength and dividend consistency.
The outlook remains positive given robust refining margins and a diversified business model, but risks include volatile energy markets and declining revenue trends. With 57% of analysts rating it a Buy and a consensus price target of $201.50 (MarketBeat, July 2026), the stock offers value with income potential, though investors should weigh execution risks against sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
